EffePharm is a biotech company that develops clinically backed bioactive ingredients and advanced delivery technologies (including LipoAvail liposomes, CelleSperse micelles, and EncapCirc microencapsulation) to improve solubility, stability, and bioavailability of compounds for health and wellness applications. Its flagship NMN products, Uthever and UthPeak NMNH (the latter with clinical data and Self-GRAS status), anchor its healthy-aging and nutrition offerings, complemented by the Effe-PLUS platform for customized, scalable ingredient delivery across nutrition and personal care. Serving 50+ countries with patents and partnerships, EffePharm translates biotech innovation into market-ready solutions through research-backed, customized formulations.
AI named EffePharm from December 2025 to January 2026.